Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Present affiliation: Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States.
Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Can J Diabetes. 2019 Jul;43(5):309-315.e2. doi: 10.1016/j.jcjd.2018.11.003. Epub 2018 Nov 17.
Diabetic ketoacidosis (DKA) is a common acute complication of diabetes mellitus and is associated with significant morbidity and mortality. There is currently a paucity of data concerning the Canadian experience with DKA. We aimed to characterize the acute management and course of DKA at several Canadian hospitals.
We performed a retrospective cohort study of patients admitted to 3 teaching hospitals in Edmonton, Canada. We extracted clinical and laboratory data from the medical charts of patients admitted to general internal medicine wards or intensive care units with moderate or severe DKA.
We included 103 admissions (84 patients) in our study. The majority (68.9%) had type 1 diabetes and presented with severe DKA (60.2%). In the first 24 h, the median (interquartile range) intravenous fluid received was 7.0 (5.5 to 8.8) litres; 23.3% received a priming insulin bolus, 24.3% received bicarbonate and 91.3% received potassium. Hypoglycemia was relatively rare (5.8%), but hypokalemia was common (41.7%). The median time to anion gap ≤12 mmol/L was 8.8 (6.0 to 12.3) h. In 27.1% of cases, intravenous insulin was stopped prior to subcutaneous insulin administration, with a median of 95 (30 to 310) min elapsing before subcutaneous insulin was given. DKA-related mortality was 2.9%.
The acute management of DKA was generally aligned with clinical guidelines. Areas for improvement include preventing hypokalemia by proactively increasing potassium repletion, reducing initial insulin boluses, administering subcutaneous insulin before stopping intravenous insulin and administering sodium bicarbonate judiciously. Protocols and preprinted order sets may be helpful, especially in smaller centres.
糖尿病酮症酸中毒(DKA)是糖尿病常见的急性并发症,与显著的发病率和死亡率相关。目前,加拿大关于 DKA 的经验数据很少。我们旨在描述几家加拿大医院的 DKA 急性管理和病程。
我们对加拿大埃德蒙顿的 3 家教学医院的住院患者进行了回顾性队列研究。我们从入住普通内科病房或重症监护病房的中度或重度 DKA 患者的病历中提取临床和实验室数据。
我们的研究纳入了 103 例住院患者(84 例患者)。大多数(68.9%)患有 1 型糖尿病,表现为严重的 DKA(60.2%)。在最初的 24 小时内,中位数(四分位距)静脉补液量为 7.0(5.5 至 8.8)升;23.3%的患者接受了胰岛素冲击量,24.3%的患者接受了碳酸氢盐,91.3%的患者接受了钾补充。低血糖相对少见(5.8%),但低血钾很常见(41.7%)。阴离子间隙≤12mmol/L 的中位数时间为 8.8(6.0 至 12.3)小时。在 27.1%的病例中,在开始皮下胰岛素治疗之前停止了静脉胰岛素治疗,开始皮下胰岛素治疗前中位数有 95(30 至 310)分钟的时间间隔。与 DKA 相关的死亡率为 2.9%。
DKA 的急性管理总体上符合临床指南。需要改进的方面包括通过主动增加钾补充来预防低钾血症,减少初始胰岛素冲击量,在停止静脉胰岛素治疗前给予皮下胰岛素治疗,以及谨慎使用碳酸氢钠。方案和预印医嘱单可能会有所帮助,尤其是在较小的中心。